6. A1C, ApoE & The Future of Knowing What’s Coming

This episode opens with a celebration—Voloridge was named the Best Midsize Business to Work For in South Florida by the Sun Sentinel—and quickly shifts into one of the most impactful conversations yet. Greg, Barry, and David break down two of the most powerful (and misunderstood) markers of long-term health: A1C and ApoE protein. First, David unpacks the science behind A1C—a marker of long-term blood sugar regulation—and explains why it’s consistently showing up across our models as a strong predictor of disease. 

The team explores why even fit individuals can have high A1C, how it differs from insulin and glucose, and what actions can actually help lower it. Then, they turn to ApoE protein, a rising star in the world of cognitive health prediction. While many people know the ApoE gene, David explains why the protein may be even more valuable for early detection of cognitive decline—and how it connects to future offerings in the Volo platform. In this episode: What A1C really measures—and why it matters for metabolic and cardiac health How diet, exercise, CGMs, and stress affect A1C—and how to act on it 

Why the ApoE protein is showing promise beyond genetic testing The difference between genetics, epigenetics, and proteomics How we’re building tools to make this kind of insight available to everyone The conversation wraps with another round of underrated or overrated, where Greg, David, and Barry weigh in on everything from zone 2 cardio to CGMs and AI health coaches. This is a clear, candid, and deeply useful look at how data science is redefining what we can know—and what we can do—about our health.